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1. Introduction 
Patients with chronic renal disease (CRD) represent an important segment of Tunisian 
population, and mostly because of the high risk of cardiovascular disease (CVD) associated 
with renal insufficiency, detection and treatment of chronic renal disease is now a public 
health priority (Abderrahim E et al., 2001, Ben Maïz H et al., 2006, Counil E et al., 2008). The 
increased incidence of CVD is likely to be the result of a high prevalence of both traditional 
risk factors, such as diabetes mellitus, hypertension, dyslipidemia and smoking. Non 
traditional risk factors, such as hyperhomocysteinemia, oxidative stress and inflammation 
have been taken into account. 
 Homocysteine (Hcy) is an amino acid that circulates in the blood. An elevated serum 
concentration of homocysteine is a known risk factor for atherosclerosis and is associated 
with an increased risk of myocardial infraction and health. Accumulating evidence suggests 
that the Hcy thioester metabolite, hcy-thiolactone, has an important role in 
atherothrombosis. Hcy-thiolactone is a product of an error-editing reaction in protein 
biosynthesis, which forms when Hcy is mistakenly selected by methionyl-tRNA synthetase. 
The thioester chemistry of Hcy-thiolactone underlies its ability of form isopeptide bonds 
with protein lysines residues, which impairs or alters protein function. Protein targets for 
modification by Hcy-thiolactone include fibrogen, LDL, HDL, albumin, heamoglobin and 
ferritin. Pathophysiclogical consequences of protein N-homocyteinylation include protein 
and cell damage, activation of an adaptive immune response, synthesis of auto-antibodies 
against N-hcy-proteins, and enhanced thrombosis caused by N-hcy-fibrogen. The 
development of highly sensitive chemical and immunohistochemical assays has provided 
evidence for the contribution of the Hcy-thiolactone pathway to pathophysiology of the 
vascular system. In particular, conditions predisposing to atherosclerosis, such as genetic or 
dietary hyperhomocysteinemia, have been shown to lead to elevation of Hcy-thiolactone 
and N-hcy-protein. 
Oxidative stress plays an important role in the pathogenesis of atherosclerosis and 
cardiovascular disease. Reactive oxygen species (ROS) production is toxic via their effects on 
cellular components such as denaturing proteins, membrane lipids and DNA. Oxidative 
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stress may be defined as an imbalance between the production and degradation of ROS such 
as superoxide anion, hydrogen peride, lipid peroxides and peroxynitrite. Enzymatic 
inactivation of ROS is achieved mainly by glutathione peroxydase (GPx), superoxidase 
dismutase (SOD) and catalase. GPx, the ubiquitous intracellular form and key antioxidant 
enzyme within most cells, including the endothelium, uses glutathione to reduce hydrogen 
peroxidase to water and lipid perides to their respective alcohols, and it also acts as a 
peroxynitrite reductase. In mice GPx deficiency results in abnormal vascular and cardiac 
function and structure. Similarly, SOD is represented by three different ubiquitously 
expressed enzymes that convert superoxide anion to hydrogen peroxide: cytosolic copper- 
and zinc-containing SOD, mitochondrial manganese-containing SOD and extracellular SOD. 
Extracellular SOD is most active in the vessel wall and has been shown to regulate the 
availability of nitric oxide by scavenging superoxide anion.  
The presence of inflammation is an important element in the pathogenesis of atherosclerosis. 
Two pathaways are activated during the process: the protein kinase C and nuclear factor-
kappa B (NF-kB) pathways. This lead to upregulation of genes that trigger the activation of 
angiotension converting enzyme, the local production of angiotensine II and the expression 
of adhesion molecules on the surface of endothelial cells. These events can result in 
endothelial dysfunction. The most extensively studied biomarker of inflammation in 
cardivasular disease is CRP. This is a circulating pentraxin that has a major role in human 
innate immune response and provides a stable plasma biomarker for low-grade systemic 
inflammation. It is predominantly produced in the liver. CRP has been implicated in 
multiple aspects of atherogenesis and plaque vulnerability, including expression of 
adhesion molecules, induction of NO, altered complement function and inhibition of 
intrinsic fibrinolysis. Procedures for its measurement are well standardized and automated 
and high-sensitivity assays (hs-CRP) are widely available. Increased CRP levels associated 
with increased prevalence of underlying atherosclerosis. 
Studies of all Tunisian patients are nondialyzed chronic kidney disease, and with 
nondiabetic renal disease. Patients according to serum creatinine levels were sub-classified 
as follows: moderate renal failure, severe renal failure and end-stage renal disease. 
Etiologies of chronic renal disease in patients were chronic glomerular nephritis, chronic 
tubulointerstitial nephropathy, vascular nephropathy and unknown cause. Cardiovascular 
complications in all groups were diagnosed by echocardiography and electrocardiography. 
Patients with cardiovascular complications included cardiac insufficiency and left 
ventricular hypertrophy. 
2. Homocysteine, paraoxonase activity and renal diseases 
Homocysteine (Hcy) as a thiol-containing amino acid has gained great notoriety, since 
elevation of its plasma concentrations, a condition known as hyperhomocysteinemia, is 
correlated with many different diseases, in particular cardiovascular disease (Cavalca V et 
al., 2001, Kerkeni M et al., 2006), and end-stage renal disease (ESRD) (Ducloux D et al., 2000, 
Perna AF et al., 2004). Serum paraoxonase 1 (PON1) is an oxidant-sensitive enzyme that 
inhibits the atherogenic oxidation of low density lipoprotein (LDL). PON1 activity is also 
implicated in protection against cardiovascular disease (Mackness M et al., 2004). Some 
studies found that the paraoxonase protein (PON1), carried on high density lipoprotein 
(HDL), has homocysteine thiolactone (HcyT) hydrolase activity and protects against protein 
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homocysteinylation in vitro (Jakubowski H et al., 2000, Jakubowski H, 2000). A possible 
molecular mechanism underlying hyperhomocysteinemia involves metabolic conversion of 
Hcy by methionyl-tRNA synthetase (MetRS) to HcyT, which then reacts with lysine residues 
in proteins, damaging their structure and impairing their physiological activities. HcyT is 
known to be cytotoxic in experimental animals and induces apoptotic death and 
proinflammation process in cultured human vascular endothelial and in primary human 
umbilical vein endothelial cells (HUVEC) (Kerkeni M et al., 2006). The extent of HcyT 
synthesis and protein homocysteinylation in human vascular endothelial cells depends on 
levels of Hcy, methionine, folate and HDL that are linked to vascular disease. In addition, 
hyperhomocysteinemia and paraoxonase activity are involved in the development of 
cardiovascular complications in patients with chronic renal disease and in patients 
undergoing hemodialysis.  
We reported in previous studies that hyperhomocysteinemia, oxidative stress and 
paraoxonase activity are risk factors for cardiovascular disease and the severity of coronary 
artery disease in Tunisian population (Kerkeni M et al., 2008). The association between 
chronic renal disease, homocysteine and paraoxonase activity have been taken into account, 
and we reported that the development of cardiovascular complications related to end-stage 
renal disease (ESRD) (Kerkeni M et al., 2009). The coexistence of a high level of Hcy and a 
low PON1 concentration increases the severity of renal disease. In hyperhomocysteinemia 
condition, Hcy occurs in human blood in several forms. The most reactive is homocysteine 
thiolactone which it’s detoxifies by Hcy-thiolactonase activity of PON1. We hypothesize that 
HcyT can also increase cellular toxicity in renal function via protein homocysteinylation 
participates in glomerular sclerosis and in the development of ESRD.  
3. Endothelial NO synthase, methylenetetrahydrofolate reductase (MTHFR) 
gene polymorphisms and renal diseases 
Epidemiologic studies have shown that dyslipidemia, diabetes mellitus, obesity, 
hypertension, and cigarette smoking are risk factors for cardiovascular complications. 
Assessment of these metabolic or lifestyle risk factors has, however, been ineffective in 
incompletely predicting the severity of renal disease and the development of CVD, 
suggesting that specific genetic predisposition should also be taken into account (Nordfors L 
et al., 2002). 
The vascular endothelium modulates blood vessel wall homeostasis through the production 
of factors regulating vessel tone, coagulation state, cell growth, cell death, and leukocyte 
trafficking. One of the most important endothelial cell products is nitric oxide (NO), which 
is synthesized from L-arginine by enzyme endothelial nitric oxide synthase (eNOS). NO 
plays a key role in the relaxation of vascular smooth muscle, inhibits platelet and leukocyte 
adhesion to the endothelium, reduces vascular smooth muscle cell migration and 
proliferation, and limits oxidation of the atherogenic LDLs. NO may modulate 
homocysteine concentration directly by inhibiting methionine synthase, the enzyme that 
synthesizes methionine from homocysteine and 5-methyltetrahydrofolate. Alternatively, 
NO may modulate Hcy concentrations indirectly via folate catabolism by inhibiting the 
synthesis of ferritin, a protein that promotes the irreversible oxidative cleavage of folate. 
Although low folate concentrations are associated with hyperhomocysteinemia, which is a 
risk factor for atherosclerosis, the relative contributions of these potential mechanisms to 
Hcy modulation in vivo remain unclear. 
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Glomerular microcirculation is involved in the deterioration of renal function. Among 
several factors that regulate renal hemodynamics, NO (nitric oxide) has been reported to be 
critical. In the vascular endothelium, NO is produced by endothelial NO synthase (eNOS). 
NO production can be influenced by polymorphisms of the eNOS gene. Polymorphisms in 
exons may alter the three-dimensional structure of the enzyme, and those in introns may 
change the transcriptional activity (Tesauro M et al., 2000). These can lead to a decrease in 
NO production and, subsequently, an increase in arterial pressure or intraglomerular 
hypertension and produce renal damage. Previous studies have shown the polymorphisms 
of the eNOS gene are associated with the progression of nondiabetic end stage renal disease 
(ESRD). Several polymorphisms have been identified in the eNOS gene, among which is one 
located in exon 7 (G894T), which modifies its coding sequence (Glu298→Asp). The G894T 
polymorphism was reported to be associated with hypertension, diabetic nephropathy and 
ESRD (Shin Shin Y et al., 2004). Furthermore, in ESRD, mean total homocysteine levels are 
commonly elevated, and the methylenetetrahydrofolate reductase (MTHFR) gene 
polymorphisms may also be associated with renal disease. The eNOS and MTHFR gene 
polymorphisms have been shown to be associated with cardiovascular disease. We reported 
in previous studies that the eNOS and MTHFR gene polymorphisms were associated with 
the presence of cardiovascular disease (Kerkeni M et al., 2006a et b). However, the 
relationship between eNOS, MTHFR gene polymorphisms and cardiovascular disease in 
Tunisian patients with chronic renal disease has been examined. We investigated that (a) the 
relationship of these gene polymorphisms with the presence and the severity of renal 
disease, and (b) their relationships with CVD in these patients (Kerkeni M et al., 2009). 
4. The mechanisms of homocysteine and paraoxonase activity to induce 
renal diseases  
In our studies, prevalence of hyperhomocysteinemia was present in 94 % of Tunisian 
patients. We found that an increased Hcy levels in patients with moderate renal failure to 
ESRD. This observation was showed by numerous clinical studies, but the pathogenic role 
of increased Hcy Levels in the progression of ESRD remains controversial and the 
mechanisms how Hcy induced renal toxicity are still unknown. Recent studies showed the 
pathogenic action of Hcy in the glomeruli or in the kidney, such as local oxidative stress, 
endoplasmic reticulum stress, homocysteinylation, hypomethylation and glomerular 
mesangial cell apoptosis via activation of p38-mitogen-activated protein kinase (Yi F and Li 
PL, 2008). In hyperhomocysteinemia condition, Hcy occurs in human blood in several 
forms. The most reactive is homocysteine thiolactone (HcyT). It spontaneously 
homocysteinylates proteins impairing their structures and functions. An increase in HcyT 
can itself lead to inactivation of PON1 as it has been demonstrated by in vitro studies or 
negatively regulate PON1 gene expression. Furthermore, we showed in previous study that 
HcyT might possess stronger cytotoxicity and pro-inflammation properties in primary 
human umbilical vein endothelial cells. We hypothesize that HcyT can also increased 
cellular toxicity in renal function via protein homocysteinylation. There is considerable 
evidence that protein homocysteinylation participates in glomerular sclerosis and in the 
development of ESRD. In this regard, Perna et al. have reported that plasma 
homocysteinylation increased in ESRD patients subject to hemodialysis (Perna AF et al., 
2006). It was demonstrated that in patients with terminal renal failure without dialysis 
protein homocysteinylation is significantly enhanced which may contribute to the 
www.intechopen.com
 
Cardiovascular Complications in Renal Diseases 
 
165 
atherogenesis and progression of ESRD in these patients. Another interesting mechanism 
that possible mediates glomerular injury or sclerosis induced by homocysteinylation is the 
irreversible homocysteinylation of long-lived proteins in connective tissue protein are 
especially susceptible to Hcy and HcyT attacks. 
Hyperhomocysteinemia and a low PON1 activity were associated in patients with each 
etiology except the unknown cause. We showed an increased Hcy levels in patients with 
chronic tubulointerstitial nephropathy than patients with glomerular nephropathy. 
Hyperhomocysteinemia is able to promote glomerular damage and generate 
tubulointerstitial lesions. O’Riodan et al. showed that chronic endothelial nitric oxide 
synthase (eNOS) inhibition actuates endothethelial mesenchymal transformation in chronic 
kidney disease (O’Riordan E et al., 2007). Several studies have demonstrated that the 
bioavailability of NO is decreased in hyperhomocysteinemia. In addition, we found that 
patients with vascular nephropathies showed an increased hyperhomocysteinemia than 
patients with glomerular nephropathy. Hyperhomocysteinemia and a low PON1 activity 
were markedly associated in CRD patient with cardiovascular complications including 
cardiac insufficiency and left ventricular hypertrophy. Some studies have shown that 
hyperhomocysteinemia induced hypertension and ventricular hypertrophy. Given the 
similarity of pathological changes between glomerular injury and Hcy induced arterial 
damages, such as endothelial injury, cell proliferation or growth, increased matrix 
formation, and aggregated proteoglycan, it is assumed that an increase in plasma Hcy levels 
may also directly act on glomerular and  tubulointerstitial cells, resulting in glomerular 
damage and tubulointerstitial lesions. Moreover, an impaired renal function will lead to a 
further increase in plasma Hcy levels which in turn exaggerates the progression of 
glomerular injury, resulting in a vicious cycle and consequent glomerulosclerosis and ESRD. 
In addition, Hcy may also produce detrimental actions or increase the risk of cardiovascular 
disease by decreasing plasma or tissue adenosine levels. It is well known that adenosine 
evokes several biological actions in the cardiovascular system and participates in the 
regulation of the renal function, including renal glomerular perfusion. It was demonstrated 
that chronic elevations of the plasma Hcy concentration in rats resulted in aretiosclerotic 
changes and glomerular dysfunction and sclerosis accompanied by sustained low level of 
plasma adenosine. Decreased adenosine concentrations during hyperhomocysteinemia may 
be due to an enhanced activity of a bidirectional enzyme, S-adenosylhomocysteine 
hydrolase. Due to space limitations, some other interesting topics related to the possible 
mechanisms mediating Hcy-induced glomerular and tubulointerstitial toxicities are not 
included, such as activation of proinflammatory factors, increased homocysteine thiolactone 
levels, and Hcy induced abnormal mitochondrial biogenesis. 
5. The mechanisms of the eNOS and MTHFR gene mutations to induce renal 
diseases  
We reported an association between the common G894T polymorphism of the eNOS and 
the presence of renal disease. We found that the eNOS 894T allele was markedly associated 
with severity of renal disease in patients with nondiabetic renal disease. Furthermore, eNOS 
G894T mutation was increased in CRD patients with cardiovascular complications included 
cardiac insufficiency and left ventricular hypertrophy. In the vascular endothelium, NO is 
produced by eNOS and implicated in numerous aspects of renal vascular control and 
function. It is thought to exert a vasculoprotective effect by modulation of kidney blood flow 
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through counterbalancing the effects of the renin-angiotensin system. A deficiency of the 
endogenous vasodilatator NO has been implicated as a potential cause of chronic renal 
diseases and in end-stage renal failure. NO production can be influenced by polymorphisms 
of the eNOS gene. These can lead to a decrease in NO production and, subsequently, an 
increase in arterial pressure or intraglomerular hypertension and renal damage. 
Polymorphisms in exons may alter the three-dimensional structure of the enzyme, and may 
change the transcriptional activity (Tesauro M et al. 2000). The eNOS G894T variant leads to 
an amino acid substitution of aspartate for glutamate at position 298 of the protein. Tesauro 
et al. showed that an in vitro study the eNOS protein with aspartate, but not glutamate, at 
position 298 is subject to cleavage by endogenous protease and produces 35-kDa amino-
terminal and 100-kDa carboxyl-terminal fragments. Nevertheless, Tesauro et al. found that 
significant potential structure changes in the Chou-Fasman secondary structure and pointed 
out that the coding region polymorphism has functional consequences. 
We therefore speculate that, in vivo, the eNOS 894GT and 894TT genotype leads to alter NO 
production, endothelial dysfunction, promotes renal hemodynamic dysfunction, and 
aggravate the extent of renal disease. With chronic eNOS enzyme dysfunction, decreased 
NO production may contribute to raise cardiovascular complications as well as micro and 
marcovascular damage. Previous studies were interested the effect of MTHFR genotypes on 
total homocysteine in patients with renal failure. However, plasma total homocysteine 
increases as renal function declines; it is elevated in the vast majority of patients with ESRD. 
The glomerular filtration rate is a strong determinant of plasma homocysteine 
concentration, even in individuals with very mild renal dysfunction. As reviewed by 
Brasttstron and Wilcken, almost every study in which renal diseases has shown a highly 
significant positive correlation between serum creatinine and Hcy concentrations. The total 
Hcy levels increase in patients with moderate renal failure and can be >100 M in patients 
with ESRD. Nevertheless, several studies showed that MTHFR C677T polymorphism 
aggravates hyperhomocysteinemia in hemodialysis patients. However, the association 
between MTHFR polymorphisms and the risk of cardiovascular disease in patients with 
renal disease remains controversial.  
In our studies, MTHFR polymorphisms were not associated with the presence and the 
severity of renal disease in CRD patients, and we found also a lack association with 
cardiovascular complications in CRD patient. On the other hand, hyperhomocysteinemia 
was founded in these patients, and Hcy levels increased not only in ESRD patients but 
increased markedly in patients with cardiovascular complications. We hypothesize that the 
synergic effects of the eNOS G984T variant and hyperhomocysteinemia induced less NO 
production and contribute to the extent of severity of renal disease and induced 
cardiovascular damage. 
6. Conclusion 
Hyperhomocysteinemia and low PON1 activity are associated with chronic renal disease 
and markedly associated in Tunisian patients with cardiovascular complications. We 
postulate that with chronic toxicity induced by hyperhomocysteinemia may contribute to 
the severity of renal disease and increase the incidence of cardiovascular disease in patients. 
Some key targets in these pathogenic pathways must be identified to direct toward 
prevention or treatment of ESRD associated with hyperhomocysteinemia which is 
particularly important since so far there are no efficient Hcy lowering and Hcy detoxifying 
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strategies being used in CRD patients. The G894T polymorphism of the eNOS gene is 
associated with the presence and the severity of renal disease in Tunisian population. The 
eNOS G984T variant and hyperhomocysteinemia both increase the extent of renal disease, 
and the development and progression of cardiovascular complications.  
7. Acknowledgments 
Author expresses his sincere appreciation to Prof. A. Miled (Laboratory of Biochemistry, 
CHU. F. Hached, Sousse, Tunisia) and Prof F. Trivin (Laboratory of Biochemistry, Saint-
Joseph Hospital, Paris, France) for their continued direction and encouragement throughout 
the study. 
8. References 
Abderrahim E, Zouaghi K, Hedri H, et al. (2001). Renal replacement therapy for diabetic 
end-stage renal disease. Experience of a Tunisian hospital centre. Diabetes Metab; 
27:584-90. 
Ben Maïz H, Abderrahim E, Ben Moussa F, Goucha R, Karoui C(2006). Epidemiology of 
glomerular diseases in Tunisian from 1975 to 2005. Influence of changes in 
healthcare and society. Bull Acad Natl Med;190:403-16. 
Cavalca V, Cighetti G, Bamonti F, et al. (2001). Oxidative stress and homocysteine in 
coronary artery disease. Clin Chem;47:887-92. 
Counil E, Cherni N, Hkarrat M, Achour A, Trimech H. (2008). Trends of incidence dialysis 
patients in Tunisia between 1992 and 2001. Am J Kidney Dis;51:463-70. 
Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM. (2000). Serum total homocysteine 
and cardiovascular disease occurrence in chronic, stable renal transplant recipients: 
a prospective study. J Am Soc Nephrol;11:134-137. 
Jakubowski H, Zhang L, Bardeguez A, and Aviv A. (2000). Homocysteine thiolactone and 
protein homocysteinylation in human endothelial cells: Implications for 
atherosclerosis. Circ Res;87:45-51. 
Jakubowski H. (2000). Calcium-dependent human serum homocysteine thiolactone 
hydrolyse: A protective mechanism against protein N- homocysteinylation. J Biol 
Chem;275:3957-62. 
Kerkeni M, Addad F, Chauffert M, et al. (2006a). Hyperhomocysteinemia, endothelial nitric 
oxide synthase polymorphism, and risk of coronary artery disease. Clinical 
Chemistry; 52: 53-58. 
Kerkeni M, Addad F, Chauffert M, et al. (2006b). Hyperhomocysteinemia, 
methylenetetrahydrofolate reductase polymorphism and risk of coronary artery 
disease. Ann Clin Biochem; 43: 1-7. 
Kerkeni M, Addad F, Chauffert M, et al. (2006). Hyperhomocysteinemia, paraoxonase 
activity and risk of coronary artery disease. Clin Biochem;39:821-5. 
Kerkeni M, Added F, Ben Farhat M, et al. (2008). Hyperhomocysteinemia and parameters of 
antioxidative defence in Tunisian patients with coronary heart disease. Ann Clin 
Biochem;45:193-98. 
Kerkeni M, Letaief A, Achour A, Miled A, Trivin F and Maaroufi K. (2009). Endothelial 
nitric oxide synthase, Methylenetetrahydrofolate reductase polymorphisms, and 
www.intechopen.com
 
Chronic Kidney Disease and Renal Transplantation 
 
168 
cardiovascular complication in Tunisian patients with nondiabetic renal disease. 
Clinical Biochemistry ;42:958-64. 
Kerkeni M, Letaief A, Achour A, Miled A, Trivin F, and Maaroufi K. ( 2009). 
Hyperhomocysteinemia, paraoxonase concentration and cardiovascular 
complication in Tunisian patients with nondiabetic renal disease. Clinical 
Biochemistry;42:777-82. 
Kerkeni M, Tnani M, Chuniaud L, et al. (2006). Comparative study on in vitro effects of 
homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a 
stronger proapoptotic and proinflammation homocysteine thiolactone. Mol Cell 
Biochem;291:119-26. 
Mackness M, Durrington P, Mackness B. (2004). Paraoxonase 1 activity, concentration and 
genotype in cardiovascular disease. Curr Opin Lipidol;15:399-404. 
Nordfors L, Stenvinkel P, Marchlewska A, et al. (2002) Molecular genetics in renal medicine: 
what can we hope to achieve? Nephrol Dial Transplant;17:5-11. 
O’Riordan E, Mendelev N, Patschan S, et al. (2007 ). Chronic NOS inhibition actuates 
endothelial mesenchymal transformation. Am J Physiol Heart Circ Physiol;292 :285-
94. 
Perna AF, Ingrosso D, Satta E, Lombardi C, Acanfora F, De Santo NG. (2004). Homocysteine 
metabolism in renal failure. Curr Opin Clin Nutr Metab Care;7:53-57. 
Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG. (2006). Increased 
plasma protein homocysteinylation in hemodialysis patients. Kidney Int;69 :869-76.  
Shin Shin Y, Hong Baek S, Yuk Chang K, et al. (2004). Relation between eNOS Glu298Asp 
polymorphism and progression of diabetic nephropathy. Diabetes Research and 
Clinical Practice;65:257-65. 
Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. (2000). Intracellular 
processing of endothelial nitric oxide synthase isoforms associated with differences 
in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. 
glutamate at position 298. Proc Natl Acad Sci USA;97:2832-5. 
Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. (2000). Intracellular 
processing of endothelial nitric oxide synthase isoforms associated with differences 
in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. 
glutamate at position 298. Proc Natl Acad Sci USA;97:2832-5. 
Yi F, Li PL.(2008). Mechanisms of homocysteine induced glomerular injury and sclerosis. 
Am J Nephrol;28:524-264. 
www.intechopen.com
Chronic Kidney Disease and Renal Transplantation
Edited by Prof. Manisha Sahay
ISBN 978-953-51-0003-4
Hard cover, 226 pages
Publisher InTech
Published online 10, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This valuable resource covers inpatient and outpatient approaches to chronic renal disease and renal
transplant with clinical practicality. This first section of the book discusses chronic disease under distinct topics,
each providing the readers with state-of-the-art information about the disease and its management. It
discusses the fresh perspectives on the current state of chronic kidney disease. The text highlights not just the
medical aspects but also the psychosocial issues associated with chronic kidney disease. The latest
approaches are reviewed through line diagrams that clearly depict recent advances. The second section of the
book deals with issues related to transplant. It provides effective and up-to-date insight into caring for your
transplant patients.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Mohsen Kerkeni (2012). Cardiovascular Complications in Renal Diseases, Chronic Kidney Disease and Renal
Transplantation, Prof. Manisha Sahay (Ed.), ISBN: 978-953-51-0003-4, InTech, Available from:
http://www.intechopen.com/books/chronic-kidney-disease-and-renal-transplantation/cardiovascular-
complications-in-renal-diseases
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
